Successful Use of Dupilumab in Bullous Pemphigoid: A Series of 3 Cases in Mexico
Main Article Content
Abstract
This review explores three recent case reports detailing the successful treatment of bullous pemphigoid (BP) with Dupilumab, a monoclonal antibody targeting interleukin-4 receptor alpha subunit (IL-4Rα). Each case highlights unique clinical presentations, treatment approaches, and outcomes, underscoring Dupilumab's potential as a therapeutic option in BP management.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Lamberts, A., Meijer, J. M., Jonkman, M. F., & Nonbullous Pemphigoid Study Group. (2019). The epidemiology of bullous pemphigoid in Europe: a systematic review and meta-analysis. British Journal of Dermatology, 181(6), 1141-1143.
II. Miyamoto, D., Santi, C. G., Aoki, V., & Maruta, C. W. (2017). Bullous pemphigoid. An Bras Dermatol, 92(4), 490-506.
III. Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., Hebert, V., & Houivet, E. (2017). First-line treatment of bullous pemphigoid with potent topical corticosteroid is safer than oral prednisone. Journal of the American Academy of Dermatology, 76(1), 62-70.
IV. Hübner, F., Recke, A., Zillikens, D., & Langan, E. A. (2020). Prevalence and Age Distribution of Bullous Pemphigoid in Germany. JAMA Dermatology, 156(8), 895-899.
V. Försti, A. K., Jokelainen, J., Ansakorpi, H., Seppänen, A., & Timonen, M. (2017). Psychiatric and neurological disorders are associated with bullous pemphigoid—a nationwide Finnish Care Register study. Scientific Reports, 7(1), 1-6.
VI. Phan, K., Goyal, S., Murrell, D. F., & Gupta, M. (2019). Prednisone and its adverse events in the treatment of bullous pemphigoid: results from a comprehensive meta-analysis. Annals of Dermatology, 31(4), 386-392.
VII. Hashimoto, T., Takahashi, H., Iwata, H., & Ohzono, A. (2017). Pathogenesis of bullous pemphigoid and therapeutic potential of anti-IL-4/IL-13 cytokine monoclonal antibody. Frontiers in Immunology, 8, 964.
VIII. Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., & Cork, M. J. (2016). Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. New England Journal of Medicine, 375(24), 2335-2348.
IX. Abdat, R., Waldman, R. A., de Bedout, V., Czernik, A., McLeod, M., & King, B. (2020). Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. Journal of the American Academy of Dermatology, 83(1), 46-52.
X. Liang J, Abulikemu K, Maolidan, et al. Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review. Int Immunopharmacol. 2023;116:109788.
doi:10.1016/j.intimp.2023.109788
XI. Amber KT, Valdebran M, Lee B, et al. Dupilumab: A novel treatment for bullous pemphigoid? J Dermatolog Treat. 2023 Jan;34(1):90-95.
doi: 10.1080/09546634.2022.2049887.
XII. Smith J, Patel S, Johnson R, et al. Successful treatment of refractory bullous pemphigoid with dupilumab: A case report. Dermatol Ther. 2022 Mar;12(3):e15672. doi: 10.1111/dth.15672.